HYPOGLOSSAL NERVE STIMULATION Archives

Tag: HYPOGLOSSAL NERVE STIMULATION

LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study

Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]

Continue Reading →

Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings

Sleep Apnea

New Study Shows Inspire Therapy Helps Reduce Hypoxic Burden

Inspire Medical Systems, Inc. participated in SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS) on June 14–17 in Baltimore, Maryland. SLEEP is the premier global forum for sleep medicine and research, jointly hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research […]

Continue Reading →

Sleep Disorders

Nyxoah Boosts Manufacturing Investment in Belgium to Fuel International Expansion

Nyxoah SA has announced an important investment in Belgium to further scale its manufacturing capacity to support its continued growth in the United States and international markets. In addition to its existing contract manufacturing operations in the United States, the Company will expand its manufacturing footprint in Wallonia, reflecting Nyxoah’s […]

Continue Reading →

nyxoah genio hypoglossal nerve stimulation

Industry News Sleep Apnea

Nyxoah Receives FDA Approval for Genio System for Treatment of OSA

Nyxoah SA announced that the U.S. Food and Drug Administration (FDA) has approved the Genio system (hypoglossal nerve stimulation) for a subset of patients with moderate to severe OSA with an Apnea-Hypopnea Index (AHI) of greater than or equal to 15 and less than or equal to 65. Genio is […]

Continue Reading →

SleepWorld Magazine Digital Health Sleep Apnea

Are We Truly Open to Change in the Approach to OSA?

Although there are more than half a billion individuals worldwide affected by moderate to severe obstructive sleep apnea (OSA), the vast majority still remain undiagnosed and many are untreated.1-2 Healthcare in the United States is facing shortages at every level—and these shortages are projected to increase sharply over the next […]

Continue Reading →

Industry News

Inspire Expands Leadership Team with Two Vice President, Senior Medical Director Appointments

Inspire Medical Systems, Inc. announced that two leading physicians in sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire as Vice President and senior Medical Director, effective April 21 and June 2, respectively. “Dr. […]

Continue Reading →

Industry News Product News

Nyxoah Receives FDA Approvable Letter for Genio Hypoglossal Nerve Stimulator

Nyxoah SA, which develops breakthrough treatment alternatives for obstructive sleep apnea (OSA) through neuromodulation, announced an update on the FDA approval process for the Genio system. On March 26, 2025, the Company announced that the U.S. Food and Drug Administration (FDA) issued an Approvable Letter regarding the Company’s Pre-Market Approval […]

Continue Reading →

SleepWorld Magazine Dental Sleep Medicine

The Path of Least Invasiveness

Treating obstructive sleep apnea (OSA) is at an exciting crossroads where therapeutic advances are coming of age in the era of precision medicine. In the past, the only option was continuous positive airway pressure (CPAP) therapy. Now, there are many effective alternatives to manage sleep apnea and even more on […]

Continue Reading →

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

Product News

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova PLC, a market-leading medical technology company, announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment arm […]

Continue Reading →

colin huntley md Hypoglossal Nerve Stimulation:

Conferences & Events Sleep Apnea

Hypoglossal Nerve Stimulation: From Concept to Clinical Practice

While continuous positive airway pressure (CPAP) is still the gold standard treatment for obstructive sleep apnea (OSA), it is well-established that many patients struggle with long-term adherence and tolerance.1 The literature indicates that CPAP non-compliance rates remain as high as 34% with little improvement over the last two decades.2 As […]

Continue Reading →